Personalis Operating Margin 2018-2026 | PSNL
Current and historical operating margin for Personalis (PSNL) over the last 10 years. The current operating profit margin for Personalis as of March 31, 2026 is -116.69%.
| Personalis Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2026-03-31 | $0.06B | $-0.10B | -161.90% |
| 2025-12-31 | $0.07B | $-0.09B | -127.54% |
| 2025-09-30 | $0.07B | $-0.08B | -117.39% |
| 2025-06-30 | $0.08B | $-0.07B | -88.89% |
| 2025-03-31 | $0.09B | $-0.07B | -77.01% |
| 2024-12-31 | $0.09B | $-0.07B | -79.07% |
| 2024-09-30 | $0.09B | $-0.07B | -83.15% |
| 2024-06-30 | $0.08B | $-0.09B | -112.35% |
| 2024-03-31 | $0.08B | $-0.10B | -132.00% |
| 2023-12-31 | $0.07B | $-0.11B | -148.65% |
| 2023-09-30 | $0.07B | $-0.12B | -166.20% |
| 2023-06-30 | $0.07B | $-0.11B | -167.65% |
| 2023-03-31 | $0.07B | $-0.12B | -169.57% |
| 2022-12-31 | $0.07B | $-0.12B | -176.92% |
| 2022-09-30 | $0.07B | $-0.10B | -149.28% |
| 2022-06-30 | $0.08B | $-0.09B | -123.68% |
| 2022-03-31 | $0.08B | $-0.08B | -101.25% |
| 2021-12-31 | $0.09B | $-0.07B | -75.58% |
| 2021-09-30 | $0.09B | $-0.06B | -68.24% |
| 2021-06-30 | $0.08B | $-0.05B | -60.24% |
| 2021-03-31 | $0.08B | $-0.04B | -55.00% |
| 2020-12-31 | $0.08B | $-0.04B | -53.85% |
| 2020-09-30 | $0.08B | $-0.04B | -47.37% |
| 2020-06-30 | $0.07B | $-0.03B | -43.84% |
| 2020-03-31 | $0.07B | $-0.03B | -38.57% |
| 2019-12-31 | $0.07B | $-0.02B | -33.85% |
| 2019-06-30 | $0.04B | $-0.01B | -26.19% |
| 2019-03-31 | $0.04B | $-0.01B | -31.43% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |